Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Eli Lilly and Company (LLY) had Cost of Goods Sold of $7.08B for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$34.12B |
|
$5.24B |
|
|
Cost of Goods Sold |
$7.08B |
$27.04B |
|
$27.67B |
|
$6.46B |
|
$96.70M |
|
$6.55B |
|
$6.55B |
|
$5.24B |
|
$5.24B |
|
$5.24B |
|
$5.24B |
|
$6.46B |
|
$7.99B |
|
900.18M |
|
903.28M |
|
$5.82 |
|
$5.80 |
|
| Balance Sheet Financials | |
$25.73B |
|
$12.91B |
|
$38.28B |
|
$64.01B |
|
$27.29B |
|
$18.32B |
|
$25.85B |
|
$53.14B |
|
$10.86B |
|
$-982.60M |
|
$10.86B |
|
949.38M |
|
| Cash Flow Statement Financials | |
$4.24B |
|
$-7.15B |
|
$3.50B |
|
$2.07B |
|
$2.82B |
|
$751.60M |
|
$628.50M |
|
$-4.07B |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.94 |
|
-- |
|
-- |
|
0.63 |
|
2.32 |
|
79.25% |
|
18.92% |
|
18.92% |
|
23.40% |
|
19.21% |
|
15.36% |
|
$792.50M |
|
-- |
|
-- |
|
-- |
|
0.53 |
|
1.23 |
|
3.01 |
|
121.25 |
|
48.24% |
|
-533.32% |
|
8.19% |
|
17.96% |
|
$11.44 |
|
$0.88 |
|
$4.69 |
|